<DOC>
	<DOCNO>NCT00995423</DOCNO>
	<brief_summary>The purpose study ass whether outcome treatment CoroflexTM Please stent inferior outcome treatment TAXUS stent .</brief_summary>
	<brief_title>Comparison Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting Stent</brief_title>
	<detailed_description>To establish effectiveness safety coronary stenting newly develop paclitaxel-eluting balloon expandable stent ( CoroflexTM Please stent , B. Bran , Melsungen , Germany ) , compare conventional paclitaxel-eluting balloon expandable stent ( TAXUS stent , Boston scientific ) treatment coronary stenosis .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>The patient must least 18 year age Significant de novo coronary artery stenosis ( &gt; 50 % visual estimation ) Patients stable ( CCS class 1 4 ) acute coronary syndrome ( unstable angina pectoris Braunwald class IB , IC , IIB , IIC , IIIB , IIIC NSTEMI ) patent atypical chest pain without symptom document myocardial ischemia , amenable stentassisted percutaneous coronary intervention The patient guardian agree study protocol schedule clinical angiographic followup , provide informed , write consent , approve appropriate Institutional Review Board/Ethical Committee respective clinical site The patient know hypersensitivity contraindication follow medication : Heparin Aspirin Both Clopidogrel TIclopidine Sirolimus , paclitaxel Stainless steel and/or Contrast medium ( patient document sensitivity contrast effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Patients true anaphylaxis prior contrast medium , however , enrol ) Systemic ( intravenous ) Sirolimus paclitaxel use within 12 month Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study History bleed diathesis know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month Current know current platelet count &lt; 100,000 cells/mm3 Hgb &lt; 10 g/dL An elective surgical procedure plan would necessitate interruption thienopyridines first 12 month post enrollment Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) Patients actively participate another drug device investigational study , complete primary endpoint followup period Patients EF &lt; 25 % Cardiogenic shock entry Acute MI patient within symptom onset &lt; 12 hour need primary angioplasty Creatinine level &gt; 3.0mg/dL dependence dialysis Patients leave main stem stenosis ( &gt; 50 % visual estimate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>stent</keyword>
</DOC>